Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28573813 | 0.84 | SPR (0.47) | SPRPOLBADORA3CYP1A2MAPT | |
| SCHEMBL3459890 | 0.83 | ADORA3 (0.48) | SPRPOLBADORA3CYP1A2MAPT | |
| SCHEMBL3459620 | 0.83 | MAPT (0.47) | SPRALDH1A1POLBADORA3CYP1A2 | |
| SCHEMBL18367334 | 0.81 | GAA (0.48) | SPRALDH1A1POLBHSD17B10ADORA3 | |
| SCHEMBL25348205 | 0.80 | SPR (0.49) | SPRALDH1A1POLBADORA3CYP1A2 | |
| SCHEMBL30540553 | 0.79 | SPR (0.48) | SPRALDH1A1POLBADORA3CYP1A2 | |
| SCHEMBL3459056 | 0.78 | APOBEC3A (0.49) | SPRALDH1A1MAPTKMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL30680968 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLBHSD17B10ADORA3MAPT | |
| SCHEMBL4051803 | 0.76 | TP53 (0.65) | POLBHSD17B10MAPTTP53KDM4E | |
| SCHEMBL25252763 | 0.74 | MAPT (0.51) | SPRALDH1A1POLBHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140038955-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2014-02-06 | — | — | US | disclosed |
| US-20140038955-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2014-02-06 | — | — | US | disclosed |
| US-8580812-B2 | Heteroaryl amide analogues as P2X7 antagonists | H. LUNDBECK A/S (DK) | 2013-11-12 | — | — | US | disclosed |
| US-8580812-B2 | Heteroaryl amide analogues as P2X7 antagonists | H. LUNDBECK A/S (DK) | 2013-11-12 | — | — | US | disclosed |
| US-8580812-B2 | Heteroaryl amide analogues as P2X7 antagonists | H. LUNDBECK A/S (DK) | 2013-11-12 | — | — | US | disclosed |
| EP-2592082-A1 | Heteroaryl amide analogues as p2x7 antagonists | H. Lundbeck A/S (DK) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013059559-A2 | COMPOUNDS AND METHODS FOR ENHANCING INNATE IMMUNE RESPONSES | GLAXOSMITHKLINE LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. Lindbeck A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. Lindbeck A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. Lindbeck A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| WO-2008124153-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | MYD88, IRF3, MAVS | SPR 3557/4885ALDH1A1 3000/4885POLB 1525/4885 |
| US-20100266509-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | P2RX7, P2RX3, P2RX2 | SPR 3310/4885ALDH1A1 2338/4885POLB 4243/4885 |
| US-20140038955-A1 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS | P2RX7, P2RX3, P2RX2 | SPR 3276/4885ALDH1A1 2733/4885POLB 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.